Nieuwe antibiotica: een overzicht

Translated title of the contribution: New antibiotics: an overview

Bregtje A. Lemkes, Olivier Richel, Marc J. Bonten, Paul D. van der Linden, W. Joost Wiersinga

Research output: Contribution to journalArticleAcademicpeer-review


The worldwide rapid increase in antibiotic resistance means that new therapeutic measures are urgently needed. Older antibiotics, such as colistin, fosfomycin, minocycline, mecillinam and temocillin, which had fallen from grace due to the development of more effective and less toxic drugs are now of renewed interest in the treatment of infections caused by multiresistant bacteria. Two new glycopeptides (oritavancin and dalbavancin) and a new oxazolidinone (tedizolid) are now registered for the treatment of acute skin and soft-tissue infections. In the treatment of infections caused by Gram-negative bacteria, cephalosporins are combined with beta-lactamase inhibitors which protect them from various beta-lactamases and also make them effective against extended spectrum beta-lactamase-producing bacteria. Examples of these are ceftolozane-tazobactam, ceftazidime-avibactam and meropenem-vaborbactam. Results of preclinical research on the effectiveness of new antibiotics are hopeful. There has been a great increase in investment in the development of new antimicrobials. Also, regulatory agencies have accelerated their assessment of these new - and urgently needed - drugs.

Translated title of the contributionNew antibiotics: an overview
Original languageDutch
Article numberD3107
JournalNederlands Tijdschrift voor Geneeskunde
Issue number9
Publication statusPublished - 13 Feb 2019


Dive into the research topics of 'New antibiotics: an overview'. Together they form a unique fingerprint.

Cite this